TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01517308
Drug: pegylated interferon alpha 2a + ribavirin
Normalized name: Pegylated interferon alpha-2a
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Comparison of different duration of drugs (48 weeks vs. 24 weeks)
Study: NCT00869908
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT00869908
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT00869908
Drug: biphasic insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT00001296
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001296
Drug: interferon-gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03510975
Drug: desmopressin melt form 120 μg
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) once daily before going to bed
Study: NCT01183013
Drug: Pioglitazone 15 mg
Normalized name: pioglitazone 15 MG
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
Study: NCT01183013
Drug: Pioglitazone 45 mg
Normalized name: pioglitazone 45 MG
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
Study: NCT01183013
Drug: Pioglitazone 30 mg
Normalized name: pioglitazone 30 MG
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone Capsules 30 mg once daily for up to 84 weeks
Study: NCT01183013
Drug: Linagliptin 5mg / Pioglitazone 45 mg FDC
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
Study: NCT01183013
Drug: Linagliptin 5mg / Pioglitazone 30 mg FDC
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
Study: NCT01183013
Drug: Linagliptin 5mg
Normalized name: LINAGLIPTIN 5MG TAB
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
Study: NCT02252302
Drug: Salbutamol inhalation
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
Study: NCT03114085
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500 mg po qd, d1-d21, every 21 days for one cycle
Study: NCT01183013
Drug: Linagliptin 5mg / Pioglitazone 15 mg FDC
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
Study: NCT01189370
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose Level:~1. 400mg twice daily, continuous.~2. 600mg twice daily, days 1-5 of each week.~3. 800mg twice daily, days 1-5 of each week.
Study: NCT02402465
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive fluticasone nasal spray
Study: NCT03263715
Drug: Tocilizumab Prefilled Syringe [Actemra]
Normalized name: tocilizumab Prefilled Syringe [Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly administration of Tocilizumab 162 mg subcutaneous from Baseline to Week 16.
Study: NCT04098393
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2.
Study: NCT04098393
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan (70mg/m2/day) administered on days -6 and -5.
Study: NCT04098393
Drug: Antithymocyte globulin (ATG)
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG will be given based on a dynamic nomogram based on the patient's absolute lymphocyte count at the start of conditioning and can result in 2 or 3 days of ATG administration.
Study: NCT04098393
Drug: Busulfan 0.8 mg/kg
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels.
Study: NCT00991029
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Loading dose of 600mg followed by 75 milligrams, oral, one tablet daily for 89 days
Study: NCT02720081
Drug: Montelukast 10 mg
Normalized name: montelukast 10 MG
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg tablet administered orally, QD, at bedtime
Study: NCT02720081
Drug: Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication
Study: NCT02845375
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
Study: NCT02845375
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
Study: NCT00825734
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)
Study: NCT00825734
Drug: Ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose Level 1 - Ixabepilone IV every 21 days (40mg/m\^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m\^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m\^2)
Study: NCT02954796
Drug: SGN-CD352A
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort -1 (4 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
Study: NCT03654729
Drug: Calmangafodipir (2 µmol/kg)
Normalized name: mangafodipir
DrugBank: Calmangafodipir (DB18398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution in 20 mL single dose glass vials
Study: NCT03654729
Drug: Calmangafodipir (5 µmol/kg)
Normalized name: mangafodipir
DrugBank: Calmangafodipir (DB18398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution in 20 mL single dose glass vials
Study: NCT01013831
Drug: Erlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01695005
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00335517
Drug: DepoDur
Normalized name: Depodur
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An epidural catheter will be placed under direct vision at the conclusion of surgery. The catheter will be advanced at least 4cm to L1 level prior to injection. Two mililiters of air will be injected through the catheter to ensure patency. Aspiration will be done to ensure no intradural injections. Then the undiluted (1 or 1.5 cc) DepoDur will be injected.
Study: NCT00052078
Drug: Sertraline (SRT)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants were treated with sertraline.
Study: NCT00387972
Drug: denagliptin (GW823093)
Normalized name: Linagliptin
DrugBank: Denagliptin (DB16134)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00588146
Drug: Pegylated Interferon Alpha2b
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly subcutaneous injection of 1 microgram/kg/week
Study: NCT00302536
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus
Study: NCT03845517
Drug: PF-06700841 15 mg
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06700841 15 mg
Study: NCT03845517
Drug: PF-06700841 30 mg
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06700841 30 mg
Study: NCT03845517
Drug: PF-06700841 45 mg
Normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06700841 45 mg
Study: NCT00645320
Drug: Ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months. Doses were flexible based on investigator's discretion.
Study: NCT05560945
Drug: 0.32% Sodium Fluoride Dentifrice Toothpaste
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toothpaste
Study: NCT01498445
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting Dose: 100 mg by mouth once daily of a 28 day cycle.
Study: NCT01498445
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.
Study: NCT01498445
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.
Study: NCT01061775
Drug: Exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.
Study: NCT00463801
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01058291
Drug: KW-6500
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twelve weeks subcutaneous injection of 1 to 6 mg for the OFF state
Study: NCT03272347
Drug: Islatravir
Normalized name: Islatravir
DrugBank: Islatravir (DB15653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected open label dose may be administered.
Study: NCT03272347
Drug: Placebo to Islatravir
DrugBank: Islatravir (DB15653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to islatravir is orally administered QD in capsule form for up to 52 weeks
Study: NCT03272347
Drug: Doravirine
Normalized name: Doravirine
DrugBank: Doravirine (DB12301)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks
Study: NCT03272347
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks
Study: NCT03272347
Drug: Placebo to Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks
Study: NCT03272347
Drug: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate
Normalized name: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fixed dose combination of 100 mg doravirine + 300 mg lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 144 weeks.
Study: NCT03272347
Drug: Doravirine/Islatravir
DrugBank: Doravirine (DB12301)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed dose combination of islatravir 0.75 mg/doravirine 100 mg orally administered QD in tablet form for 48 weeks
Study: NCT00703677
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive lithium. The dosage will be titrated over a 5-week period and then continued for an additional 6 months.
Study: NCT02774044
Drug: Survanta
Normalized name: Survanta
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00702260
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg capsule
Study: NCT01450514
Drug: Pipamperone
Normalized name: pipamperone
DrugBank: Pipamperone (DB09286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL
Study: NCT01775787
Drug: Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to either Tobacco Flavor group for 7-10 days than crossed over to Tobacco \& Menthol Flavor for 7-10 days or Tobacco \& Menthol Flavor group for 7-10 days than crossed over to Tobacco Flavor for 7-10 days
Study: NCT01535469
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 800mg orally daily for 2 weeks, then 400mg daily for 8 weeks
Study: NCT00578279
Drug: dehydrated alcohol
Normalized name: DEHYDRATED ALCOHOL
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure
Study: NCT01018745
Drug: BMS-907351 (XL184)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, 25, 50, 75, 100, 125 and 175 mg, Once daily, Until disease progression or unacceptable toxicity became apparent
Study: NCT03636308
Drug: nanoparticle albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle or day 1 and 8 of 21 day cycle.
Study: NCT02915172
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase 1 Dose Escalation: Starting dose of Lenvatinib 10 mg by mouth once daily of a 21 day cycle.~Phase 2 Dose Expansion: Starting dose of Lenvatinib is maximum tolerated dose from Phase 1.
Study: NCT00256932
Drug: alvimopan
Normalized name: Alvimopan
DrugBank: Alvimopan (DB06274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg
Study: NCT02748057
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01990573
Drug: 0.3mg/kg IV methadone HCl
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group I will receive 0.3mg/kg IV methadone HCl
Study: NCT04445090
Drug: BI 1569912
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1569912
Study: NCT01476267
Drug: dalcetrapib
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral radiolabeled dose
Study: NCT00905632
Drug: BI 207127 middle dose +SOC
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 207127 middle dose tid + SOC
Study: NCT00004276
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00905632
Drug: BI 207127 high dose+SOC
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 207127 high dose tid +SOC
Study: NCT00905632
Drug: BI 207127 low dose + SOC
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 207127 low dose tid + SOC
Study: NCT00677313
Drug: metreleptin
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metreleptin injection
Study: NCT04232644
Drug: Crushed d-amphetamine sulfate IR tablets
Normalized name: amphetamine / dextroamphetamine
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: crushed d-amphetamine sulfate IR 6 x 5 mg tablets
Study: NCT00758498
Drug: armodafinil
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/day orally, once daily in the morning for 3 days
Study: NCT00161434
Drug: valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 gram daily for 8 weeks
Study: NCT00758498
Drug: armodafinil
Normalized name: Armodafinil
DrugBank: Armodafinil (DB06413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg/day orally, once daily in the morning for 3 days
Study: NCT00308516
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined Modality Treatment:~fluorouracil 225mg/m2 IV continuous infusion days 1-42~Systemic Treatment:~5-fluorouracil 400 mg/m2 bolus 5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15
Study: NCT00308516
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combined Modality Treatment:~bevacizumab 5mg/kg IV infusion days 1, 15, and 29~Systemic Treatment:~bevacizumab 5 mg/kg days 1 and 15
Study: NCT00308516
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systemic Treatment:~oxaliplatin 85 mg/m2 days 1 and 15
Study: NCT03782987
Drug: BI 730357
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg BI 730357 tablet orally on Day 1
Study: NCT03782987
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mL of 10 mg/ mL Itraconazole oral solution in treatment period 2 only (T). Itraconazole was administered once daily for 12 days from Day -3 to Day 9.
Study: NCT02982889
Drug: LIQ865A bupivacaine formulation
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single subcutaneous injection in medial calf
Study: NCT02982889
Drug: LIQ865B bupivacaine formulation
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single subcutaneous injection in medial calf
Study: NCT02982889
Drug: 0.5% bupivacaine hydrochoride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single subcutaneous injection
Study: NCT03636308
Drug: S1
Normalized name: LS11
DrugBank: LS11 (DB05918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 is orally administered (BSA\<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA\>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle.
Study: NCT03636308
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine is given at 1000mg/m2 intravenously on d1 and 8 of each 21 day cycle.
Study: NCT00005959
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005959
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03787602
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab is a PD-L1 blocking antibody anticancer drug administered by intravenous infusion.
Study: NCT01945047
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Bolus infusion Ketamine Hydrochloride 0.50 mg/mL over 40 minutes
Study: NCT01945047
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bolus infusion of Midazolam Hydrochloride 1 mg/mL over 40 minutes
Study: NCT02065401
Drug: Deferitazole (disodium salt, granule)
Normalized name: flavodic acid, disodium salt
DrugBank: Deferitazole (DB13120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 1500 mg administered on Day 1
Study: NCT02065401
Drug: Deferitazole (disodium salt, tablet)
Normalized name: flavodic acid, disodium salt
DrugBank: Deferitazole (DB13120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 1500 mg administered on Day 1
Study: NCT02065401
Drug: Deferitazole (magnesium hydroxide salt)
Normalized name: Magnesium Hydroxide
DrugBank: Deferitazole (DB13120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 2400 mg administered on Day 1
Study: NCT02781818
Drug: Triamcinolone Acetonide 10mg/mL
Normalized name: TRIAMCINOLONE ACETONIDE 10MG/ML INJ,SUSP
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.